CIK 0001812364 · Large accelerated filer
Relay Therapeutics, Inc.
Sign in to watch- Ticker
- RLAY
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-370-8837
- Business address
- 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $120,165,474
- in 11 filings, $3.7M under 10b5-1 plans
Net −$120,165,474. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 98 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-30 | Rahmer Peter See remarks | Sale 10b5-1 | −50,000 | $19.09 | $955K | 225,857 |
| 2026-06-30 | Rahmer Peter See remarks | Grant or award 10b5-1 | +3,056 | $6.95 | $21K | 228,913 |
| 2026-06-22 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −17,717 | $17.01 | $301K | 177,461 |
| 2026-06-22 | Catinazzo Thomas Chief Financial Officer | Option exercise 10b5-1 | +56,323 | $5.04 | $284K | 233,784 |
| 2026-06-22 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −56,323 | $16.97 | $956K | 177,461 |
| 2026-06-22 | Catinazzo Thomas Chief Financial Officer | Option exercise 10b5-1 | +61,563 | $5.22 | $321K | 239,024 |
| 2026-06-22 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −61,563 | $16.97 | $1.0M | 177,461 |
| 2026-06-22 | Catinazzo Thomas Chief Financial Officer | Option exercise 10b5-1 | +51,560 | $4.45 | $229K | 229,021 |
| 2026-06-22 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −51,560 | $16.97 | $875K | 177,461 |
| 2026-06-22 | Catinazzo Thomas Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −56,323 | 0 | ||
| 2026-06-22 | Catinazzo Thomas Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −61,563 | 0 | ||
| 2026-06-22 | Catinazzo Thomas Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −51,560 | 223,440 | ||
| 2026-06-22 | Bergstrom Donald A President, R&D | Option exercise 10b5-1 | +93,456 | $4.12 | $385K | 512,013 |
| 2026-06-22 | Bergstrom Donald A President, R&D | Sale 10b5-1 | −93,456 | $16.94 | $1.6M | 418,557 |
| 2026-06-22 | Bergstrom Donald A President, R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −93,456 | 0 | ||
| 2026-06-09 | Mazumdar Claire Director | Grant or award · Stock Option (Right to Buy) | +32,947 | 32,947 | ||
| 2026-06-09 | Dable Habib J Director | Grant or award · Stock Option (Right to Buy) | +32,947 | 32,947 | ||
| 2026-06-09 | COATS LONNEL Director | Grant or award · Stock Option (Right to Buy) | +32,947 | 32,947 | ||
| 2026-06-09 | HILL LINDA A Director | Grant or award · Stock Option (Right to Buy) | +32,947 | 32,947 | ||
| 2026-06-09 | Borisy Alexis Director | Grant or award · Stock Option (Right to Buy) | +32,947 | 32,947 |
Page 2 of 17 · 329 trades